|Bid||8.50 x 2513500|
|Ask||9.30 x 11600000|
|Day's Range||8.80 - 9.05|
|52 Week Range||3.77 - 11.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Oxford BioMedica PLC (LSE:OXB) is a small-cap stock with a market capitalization of GBP £273.38M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...
Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.